Senna G E, Andri G, Dama A R, Falagiani P, Andri L
Allergology Service, Ospedale Maggiore, Verona, Italy.
Allergol Immunopathol (Madr). 2000 Jul-Aug;28(4):238-42.
Efficacy and safety of local nasal immunotherapy has been demonstrated by many placebo-controlled clinical trials. The treatment schedule consists of an induction phase at increasing dosages followed by a maintenance phase. Aim of present study has been to evaluate a new simplified treatment schedule at constant dosage.
26 grass-allergic rhinitic patients have been treated according to the new constant dosage schedule, while 15 patients in a control group were treated with conventional incremental dosage schedule. A commercial preparation of allergens incorporated into powder (Allerkin). The total cumulative dosage administered with conventional schedule resulted higher than simplified constant schedule (5,025 vs 3,000 AU). To evaluate efficacy, symptom and rescue medication scores were recorded during the spring pollen season, and a subjective overall evaluation was asked to the patients at the end of the season. The analysis of scores showed that the two treatment schedules were equivalent as regards both efficacy and safety, being side effects light and restricted to the administration site (sneezing).
The use of a constant dosage schedules is suggested for the administration of local nasal immunotherapy, having as advantage a better simplicity. Avoidance of mistakes in dosages is considered important in a therapy which is self-administered by patients.
许多安慰剂对照临床试验已证明局部鼻免疫疗法的有效性和安全性。治疗方案包括一个剂量递增的诱导期，随后是维持期。本研究的目的是评估一种新的固定剂量简化治疗方案。
26例草花粉过敏性鼻炎患者按照新的固定剂量方案进行治疗，而15例对照组患者采用传统的递增剂量方案治疗。使用一种制成粉末状的商业变应原制剂（Allerkin）。传统方案的累计总给药剂量高于简化固定剂量方案（5025对3000AU）。为评估疗效，在春季花粉季节记录症状和急救药物评分，并在季节结束时让患者进行主观总体评价。评分分析表明，两种治疗方案在疗效和安全性方面相当，副作用轻微且仅限于给药部位（打喷嚏）。
建议采用固定剂量方案进行局部鼻免疫疗法，其优点是更简便。在患者自行给药的治疗中，避免剂量错误被认为很重要。
